Analysis of the mechanism of quinolone resistance in nalidixic acid- resistant clinical isolates of Salmonella serotype Typhimurium

Journal of Medical Microbiology

Volumn 46, Issue 7, 1997, Pages 623-628

  Ruiz, J ^a   Castro, D ^b   Goni P ^a   Santamaria, J A ^b   Borrego, J J ^b   Vila, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); NALIDIXIC ACID; OUTER MEMBRANE PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DNA SEQUENCE; DRUG PENETRATION; GASTROENTERITIS; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SPAIN;

EID: 0030855150     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-46-7-623     Document Type: Article

References (34)

1. Asperilla MO, Smego RA, Scott LK. Quinolone antibiotics in the treatment of Salmonella infections. Rev Infect Dis 1990; 12: 873-889.
2. Barnass S, Franklin J, Tabaqchali S. The successful treatment of multiresistant non-enteric salmonellosis with seven day oral ciprofloxacin. J Antimicrob Chemother 1990; 25: 299-300.
3. Pichler HET, Diridl G, Stickler K, Wolf D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med 1987; 82 Suppl 4A: 329-332.
4. Neill MA, Opal SM Heelan J et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 1991; 114: 195-199.
5. Piddock LJV, Griggs DJ, Hall MC, Jin YF. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob Agents Chemother 1993; 37: 662-666.
6. Heisig P. High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyrA and gyrB genes. J Antimicrob Chemother 1993; 32: 367-377.
7. Reyna F, Huesca M, González V, Fuchs LY. Salmonella typhimurium gyrA mutations associated with fluoroquinolone resistance. Antimicrob Agents Chemother 1995; 39: 1621-1623.
8. Brown JC, Thomson CJ, Amyes SGB. Mutations of the gyrA gene of clinical isolates of Salmonella typhimurium and three other Salmonella species leading to decreased susceptibilities to 4-quinolone drugs. J Antimicrob Chemother 1996; 37: 351-356.
9. Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA 1995; 92: 11801-11805.
10. Vila J, Ruiz J, Goñi P, Jimenez de Anta MT. Detection of mutations in parC gene of quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1996; 40: 491-493.
11. Kado CI, Liu ST. Rapid procedure for detection and isolation of large and small plasmids. J Bacteriol 1981; 145: 1365-1373.
12. Marcos MA, Jimenez de Anta MT, Vila J. Correlation of six methods for typing nosocomial isolates of Acinetobacter baumannii. J Med Microbiol 1995; 42: 328-335.
13. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd edn. Approved standard M7-A2. Villanova, PA, National Committee for Clinical Laboratory Standards. 1990.
14. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. M2-A4, 4th edn. Villanova. PA. National Committee for Clinical Laboratory Standards. 1990.
15. Mortimer PGS, Piddock LJV. A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother 1991; 28: 639-653.
16. Chart H, Trust TJ. Characterization of the surface antigens of the marine fish pathogens Vibrio anguillarum, and Vibrio ordalii. Can J Microbiol 1984; 30: 703-710.
17. Filip C, Fletcher G, Wulff JL, Earhart CF. Solubilization of the cytoplasmic membrane of Escherichia coli by the ionic detergent sodium-lauryl sarcosinate. J Bacteriol 1973; 115: 717-722.
18. Hitchcock PJ, Brown TM. Morphological heterogenecity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol 1983; 154: 269-277.
19. Tsai CM, Frasch CE. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem 1982; 119: 115-119.
20. Vila J, Ruiz J, Marco F et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother 1994; 38: 2477-2479.
21. Swanberg SL, Wang JC. Cloning and sequencing of the Escherichia coli gyrA coding for the A subunit of DNA gyrase. J Mol Biol 1987; 197: 729-736.
22. Luttinger AL, Springer AL, Schmid MB. A cluster of genes that affects nucleoid segregation in Salmonella typhimurium. New Biol 1991; 3: 687-697.
23. Borrego JJ, Castro D, Jimenez-Notario M et al. Comparison of epidemiological markers of Salmonella strains isolated from different sources in Spain. J Clin Microbiol 1992; 30: 3058-3064.
24. Holmberg SD, Wachsmuth IK, Hickman-Brenner FW, Cohen ML. Comparison of plasmid profile analysis, phage typing, and antimicrobial susceptibility testing in characterizing Salmonella typhimurium isolates from outbreaks. J Clin Microbiol 1984; 19: 100-104.
25. Liu S-L, Hessel A, Sanderson KE, The XbaI-BlnI-CeuI genomic cleavage map of Salmonella typhimurium LT2 determined by double digestion, end labelling, and pulsed-field electrophoresis. J Bacteriol 1993; 175: 4104-4120.
26. Liu S-L, Sanderson KE. A physical map of the Salmonella typhimurium LT2 genome made by using XbaI analysis. J Bacteriol 1992; 174: 1662-1672.
27. Hirai K, Aoyama H, Irikura T, Iyobe S. Mitsuhashi S. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother 1986; 29: 535-538.
28. Lewin CS, Nandivada LS, Amyes SGB. Multiresistant salmonella and fluoroquinolones. J Antimicrob Chemother 1991; 27: 147-149.
29. Howard AJ, Joseph TD, Bloodworth LLO, Frost JA, Chart H, Rowe B. The emergence of ciprofloxacin resistance in Salmonella typhimurium. J Antimicrob Chemother 1990; 26: 296-298.
30. Cohen SP, McMurry LM, Hooper DC, Wolfson JS, Levy SB. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother 1989; 33: 1318-1325.
31. Cohen SP, Yan W, Levy SB. A multidrug resistance regulatory chromosomal locus is widespread among enteric bacteria. J Infect Dis 1993; 168: 484-488.
32. Hooper DC, Wolfson FC. Mechanisms of bacterial resistance to quinolones. In: Hooper DC, Wolfson JC (eds) Quinolone antimicrobial agents, 2nd edn. Washington, DC. American Society for Microbiology. 1993: 97-119.
33. Griggs DJ, Gensberg K, Piddock LJ. Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from humans and animals. Antimicrob Agents Chemother 1996; 40: 1009-1013.
34. Brown JC, Shanahah PHA, Jesudason MV, Thomson CJ. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J Antimicrob Chemother 1996; 37: 891-900.